51. Inhaled formulations and pulmonary drug delivery systems for respiratory infections
- Author
-
Hak-Kim Chan, Qi Tony Zhou, Zhi Hui Loh, Thaigarajan Parumasivam, Sharon S.Y. Leung, and Patricia Tang
- Subjects
Drug ,medicine.medical_specialty ,Antifungal Agents ,medicine.drug_class ,Surface Properties ,media_common.quotation_subject ,Antibiotics ,Pharmaceutical Science ,Pharmacology ,Antiviral Agents ,Drug Delivery Systems ,Drug Stability ,Administration, Inhalation ,medicine ,Humans ,Respiratory system ,Particle Size ,Intensive care medicine ,Adverse effect ,Respiratory Tract Infections ,media_common ,Aerosols ,business.industry ,Dry Powder Inhalers ,Dry-powder inhaler ,Anti-Bacterial Agents ,Resistant bacteria ,Targeted drug delivery ,Drug delivery ,Liposomes ,Nanoparticles ,business - Abstract
Respiratory infections represent a major global health problem. They are often treated by parenteral administrations of antimicrobials. Unfortunately, systemic therapies of high-dose antimicrobials can lead to severe adverse effects and this calls for a need to develop inhaled formulations that enable targeted drug delivery to the airways with minimal systemic drug exposure. Recent technological advances facilitate the development of inhaled anti-microbial therapies. The newer mesh nebulisers have achieved minimal drug residue, higher aerosolisation efficiencies and rapid administration compared to traditional jet nebulisers. Novel particle engineering and intelligent device design also make dry powder inhalers appealing for the delivery of high-dose antibiotics. In view of the fact that no new antibiotic entities against multi-drug resistant bacteria have come close to commercialisation, advanced formulation strategies are in high demand for combating respiratory 'super bugs'.
- Published
- 2014